Neuroscience Drug Discovery and Neurodegenerative Disease Models

The discovery of effective therapies for neurodegenerative disorders hinges on a multifaceted approach that integrates target identification, compound screening, and the development of predictive disease‐modelling systems. Central to this endeavour is the characterisation of molecular drivers—such as misfolded proteins, aberrant kinase signalling and neuroinflammation—and the translation of these insights into chemical or biological probes. Advances in high‐throughput screening platforms, structure‐guided drug design and machine‐learning algorithms have accelerated hit identification and lead optimisation. Meanwhile, cellular and animal models have evolved from simple immortalised lines and transgenic rodents to human induced pluripotent stem cell (iPSC)-derived neurons, three-dimensional organoids and humanised mouse strains. Complementary in silico models, including quantitative systems pharmacology and neuromorphic simulations, offer predictive frameworks for pharmacokinetics, target engagement and functional outcomes. Together, these strategies aim to overcome historical bottlenecks—such as the impermeability of the blood–brain barrier, species differences in drug response and the complexity of neural circuits—and to deliver candidate therapies that can halt or reverse pathology in Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis and related conditions.

Research from Nature Portfolio

Recent studies have showcased the power of integrating deep-learning with high-content phenotypic screening to identify novel small-molecule modulators of tau aggregation. By training convolutional neural networks on live-cell imaging data, researchers accelerated the prioritisation of chemical series with favourable brain-penetrant properties. Another advance has come from the application of organoid technology, where three-dimensional cortical spheroids bearing familial Alzheimer’s mutations have been used to model amyloid deposition and synaptic dysfunction. These organoids enabled the first proof-of-concept demonstration that antisense oligonucleotides can selectively reduce pathogenic transcripts in a human-derived context. Finally, cryo-electron microscopy of disease-relevant protein complexes—such as alpha-synuclein fibrils isolated from patient tissue—has provided atomic-level insights that are now guiding rational design of aggregation inhibitors with enhanced specificity.

Neuroscience Drug Discovery and Neurodegenerative Disease Models publication trend

The graph below shows the total number of articles in neuroscience drug discovery and neurodegenerative disease models across all publications each year (not limited to Nature Index journals).

Technical terms

Induced pluripotent stem cell (iPSC): Somatic cell reprogrammed to a pluripotent state, enabling patient-specific neuronal cultures.

High-throughput screening (HTS): Automated testing of large chemical libraries against biological targets or phenotypes.

Blood–brain barrier (BBB): Selective endothelial interface that restricts passage of substances from the circulation into the central nervous system.

Organoid: Three-dimensional, self-organising cell culture that mimics aspects of human tissue architecture and function.

Phenotypic screening: Assay approach that evaluates compounds based on measurable changes in cell or tissue behaviour rather than predefined molecular interactions.

References

1. Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery. Signal Transduction and Targeted Therapy (2025).
2. Neuromorphic computing for modeling neurological and psychiatric disorders: implications for drug development. Artificial Intelligence Review (2024).
3. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. International Journal of Molecular Sciences (2022).
4. High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases. Bioengineering (2021).
5. Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases. International Journal of Molecular Sciences (2021).
6. A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease. Frontiers in Pharmacology (2016).